Red blood cell-derived vesicles (RBCVs) for use in targeted delivery of thrombolytic drugs to blood clots.

Red blood cell-derived vesicles (RBCVs) for use in targeted delivery of thrombolytic drugs to blood clots.
Imperial.Tech.Pitch: Affordable technologies for an ageing society centred on the premise that within 20 years, there will be 25% fewer taxpayers to pensioners in the UK than in 2020.
Imperial.Tech.Pitch: Transition to zero pollution saw researchers and inventors from Imperial showcase their technologies and innovations that are helping companies and sectors to transition to a zero pollution future.
A fully flexible, scalable and low-cost detection platform to sense multiple protein targets simultaneously by grafting specific sequences along the backbone of a double-stranded DNA carrier.
Learn about our programme of events and sign up to be alerted for future events
The UK Cystic Fibrosis Gene Therapy Consortium (GTC) is one of the partners in a licensing agreement with Boehringer Ingelheim.
A portfolio of human colorectal adenocarcenoma cell lines including primary cell lines isolated from patients (of various Duke’s stages and histological grades) in addition to cloned cells lines genetically modified to highly express alpha integrin domains.
Proposed use Research into Charcot-Marie Tooth Disease (Type 1A). Research into autoimmune neurological disorders would be the main target market. Problem addressed Construction of models of human inherited diseases is particularly important for testing gene therapy...
Rodrigo Ledesma-Amaro is leading a research group at the interface of synthetic biology and metabolic engineering. His research lab is based in the Department of Bioengineering and the Center for Synthetic Biology and Innovation. He collaborates closely with Tom Ellis...
This fish line has been produced by gene editing and exhibits reduced cAMP binding associated with severe consequences. The fish mutant displays cardiac arrhythmia, muscular dystrophy and myofiber rupture and models a mutation found in patients with limb-girdle muscular dystrophy and AV-block.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean nec venenatis arcu. In fermentum non tellus nec vulputate. Integer accumsan, nunc sit amet porta commodo, diam sapien feugiat purus, at imperdiet arcu nisi quis dui. Etiam vel nisl sem. Proin felis nisl, fringilla eu eros ac, sodales pellentesque sem.